title: [Impact of corrective measures on fluoroquinolones prescriptions for urinary tract infections during a 2-round relevance study].
abstract: OBJECTIVE
  Evaluating the impact of corrective measures on fluoroquinolones (FQ) prescriptions for urinary tract infections (UTI) during a 2-round relevance study on a regional scale.
  
  
  METHODS
  FQ prescriptions of voluntary hospitals were checked by an infectious diseases physician and a pharmacist according to regional guidelines. A first round (R1) took place in January 2008, with feedback and proposal for personalized corrective measures in January 2009. A second round (R2) was organized in June 2009. UTI data were extracted and the results of the two rounds were compared.
  
  
  RESULTS
  Four hundred and thirty-five and 302 FQ prescriptions for UTI, coming from 28 and 24 different hospitals, were analyzed at R1 and R2, respectively. Thirty-six percent and 55% of these prescriptions were entirely in accordance with regional guidelines, at respectively R1 and R2 (P<0.001). All the analyzed criteria (choice of the molecule, dosage, duration of the treatment) significantly improved between R1 and R2. The route of administration non-significantly deteriorated. The rate of FQ prescriptions for non conform indications decreased from 24% to 12% between R1 and R2 (P<0.05).
  
  
  CONCLUSIONS
  Most hospitals of Lorraine took part in this study, confirming its feasibility on a regional scale. The regional guidelines were reviewed at the end of R2, taking into account the last national guidelines. There was a significant improvement of FQ prescriptions for UTI through better adhesion to the regional guidelines between the two rounds. This is probably due to first turn results feedback, and corrective measures suggestion.
authors.affiliation: CHU de Nancy, hôpitaux de Brabois, maladies infectieuses et tropicales, 54500 Vandoeuvre-lès Nancy, France. v.gendrin@chu-nancy.fr
authors.forename: V
authors.initials: V
authors.lastname: Gendrin
authors.forename: L
authors.initials: L
authors.lastname: Letranchant
authors.forename: S
authors.initials: S
authors.lastname: Hénard
authors.forename: E
authors.initials: E
authors.lastname: Frentiu
authors.forename: B
authors.initials: B
authors.lastname: Demore
authors.forename: C
authors.initials: C
authors.lastname: Burty
authors.forename: T
authors.initials: T
authors.lastname: May
authors.forename: T
authors.initials: T
authors.lastname: Doco-Lecompte
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003625:Data Collection / Q000379:methods* / Q000592:standards; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D019983:Guideline Adherence / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011358:Product Surveillance, Postmarketing / Q000379:methods / Q000706:statistics & numerical data; D011795:Surveys and Questionnaires; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones